Three Stem-Cell Stocks Ripe With Potential

Updated from 7:12 a.m. EDT

Investing in biotechnology companies is said to be like playing the slots, but hitting the jackpot can be even harder with stem-cell stocks.

Take Geron (GERN Quote), the worldwide leader in embryonic stem-cell research. It might very well cure cancer and paralysis one of these days. But the company has cost investors plenty, with its stock spiraling from $75 to $8 a share this decade.

But after researching the stem-cell industry for more than 10 years, WBB Securities analyst Stephen Brozak finally sees some payoffs on the horizon. Brozak believes that Geron's day will come and says some smaller players with commercial products on the way could bring more immediate rewards. ...